Study: ADT and Alzheimer's Disease May Be Linked
What's New in the VJPU?
New research in the Journal of Clinical Oncology suggests that men on androgen deprivation therapy (ADT) are at higher risk for Alzheimer's disease.
ADT is a common treatment for prostate cancer. Because androgens can fuel the growth of prostate cancer cells, the therapy aims to reduce androgen levels through surgery or regularly administered medications.
The study was conducted by researchers from the Perelman School of Medicine at the University of Pennsylvania and the Stanford School of Medicine.
They analyzed electronic medical data from 16,888 men with prostate cancer. Overall, 14% underwent ADT. The men were followed for a median of 2.7 years.
The researchers found that men on ADT had more Alzheimer's diagnoses during the follow-up period than those who did not undergo ADT. Also, the risk of Alzheimer's increased with the length of time men were on ADT.
The scientists were not certain why this association occurred. More research is needed.
Please click here to learn more about this study.